Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma - Top-Institutions - MDSpire

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma

  • By

  • Jack Y. Ghannam

  • Julian Bryan

  • Jakob Weiss

  • Daniel Kovarsky

  • David Merrell

  • Conor Messer

  • Kristy Schlueter-Kuck

  • Geoffrey G. Fell

  • Mary Jane Lim-Fat

  • Gilbert Youssef

  • Rifaquat Rahman

  • Lei Qin

  • Geoffrey S. Young

  • J. Thomas Janes

  • McKayla Van Orden

  • Kathleen L. Pfaff

  • Andrew Gans

  • Emma S. Lin

  • Raymond Y. Huang

  • Brian P. Danysh

  • Laxmi Parida

  • Shuqiang Li

  • Patrick Y. Wen

  • E. Antonio Chiocca

  • Donna Neuberg

  • Keith L. Ligon

  • Itay Tirosh

  • David A. Reardon

  • Gad Getz

  • Catherine J. Wu

  • June 12, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Dana-Farber/Harvard Cancer Center
    Dana-Farber/Harvard Cancer Center

    Boston, Massachusetts

    Key Differentiators

    • Oncology

Original Source(s)

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma

  • by Jack Y. Ghannam, Julian Bryan, Jakob Weiss, Daniel Kovarsky, David Merrell, Conor Messer, Kristy Schlueter-Kuck, Geoffrey G. Fell, Mary Jane Lim-Fat, Gilbert Youssef, Rifaquat Rahman, Lei Qin, Geoffrey S. Young, J. Thomas Janes, McKayla Van Orden, Kathleen L. Pfaff, Andrew Gans, Emma S. Lin, Raymond Y. Huang, Brian P. Danysh, Laxmi Parida, Shuqiang Li, Patrick Y. Wen, E. Antonio Chiocca, Donna Neuberg, Keith L. Ligon, Itay Tirosh, David A. Reardon, Gad Getz, Catherine J. Wu

  • June 12, 2026

Related Content

Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets

Overall survival and prognostic factors of oral cavity and oropharyngeal squamous cell carcinomas in Saudi Arabia: a population-based cohort study (2000–2019)

Viable CAR T-cells remain detectable in cerebrospinal fluid in patients with grade ≥3 ICANS despite corticosteroid therapy